CD8A and neoplasm: Intratumoral BO-112 treatment leads to remarkable tumor regression dependent on type I IFN and gamma-interferon in the mouse models.89 Furthermore, more abundant CD8+ T lymphocytes and tumor antigen specific cytotoxic T lymphocytes were found following intratumoral BO-112 treatment.